Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...